SK pharmteco

Newswire/News Agency
As a subsidiary of SK Inc., SK pharmteco is backed by the strength and stability of one of South Korea’s largest business networks. Drawing from our long-standing industry presence, we leverage our expertise, technology, and legacy of innovation to navigate the complexities of advancing small molecule and cell and gene therapies. Our integrated service offerings cover process and analytical method development, optimization, validation, analytical testing, and commercial production. Working beside our customers throughout their entire journey, we operate as ‘One Team’, collaborating on a foundation of trust and common purpose to develop and deliver therapies that change lives. Source

Actions

Share this page

Media Outlet details

Scope International
Language French
Country United States of America
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing

Recent Articles

Search

De-Risk Adenoviral Vector Development with an Adaptive Platform

|
By Bob Brousseau
| SK pharmteco
Adenoviral vector programs are too complex for a rigid, one-size-fits-all manufacturing approach. Construct design, cell line behavior, harvest conditions, purification strategy, formulation, analytics, and viral clearance can all shape the path from development to GMP.
Open in Who Shared Issue with article?

SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside

|
By Bob Brousseau
| SK pharmteco
FOR IMMEDIATE RELEASE Rancho Cordova, CA (June 23, 2026) — SK pharmteco today announced the launch of SKyvec™, its proprietary, multimodal viral vector platform. Designed to support gene therapy programs at every stage, from early research through clinical supply and commercial manufacturing, the SKyvec™ platform integrates development capabilities with global manufacturing expertise across North America and Europe to significantly accelerate clinical timelines.
Open in Who Shared View Duplicates (90) Issue with article?

SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies

|
By Bob Brousseau
| SK pharmteco
FOR IMMEDIATE RELEASE Rancho Cordova, CA (June 18, 2026) — SK pharmteco today announced a collaborative agreement with the Orphan Therapeutics Accelerator (OTXL), a non-profit, biotech focused on completing development and enabling access to stalled rare disease treatments, to support the advancement of novel therapeutic programs.
Open in Who Shared Issue with article?

Accelerating AAV5 Purification Development with High-Throughput Screening

|
By Bob Brousseau
| SK pharmteco
AAV downstream processing remains a major bottleneck in gene therapy manufacturing. For challenging serotypes such as AAV5, standard affinity chromatography conditions can lead to poor recovery, longer development timelines, and increased process complexity. This poster presents a rapid, data-driven approach for identifying robust AAV5 purification conditions.
Open in Who Shared Issue with article?

Lentiviral Vector Purification for In Vivo Applications

|
By Bob Brousseau
| SK pharmteco
Lentiviral vector (LVV) purification for in vivo gene therapy applications requires stringent impurity clearance without sacrificing vector recovery. Conventional downstream approaches can struggle to balance these needs, with resin saturation, limited throughput, and inefficient impurity removal, creating barriers to scale and product quality.
Open in Who Shared Issue with article?

Enabling In Vivo Lentiviral Therapies for Clinical and Commercial Success

|
By Bob Brousseau
| SK pharmteco
As in vivo lentiviral therapies advance from research to clinical reality, developers face increasing pressure to deliver scalable, high-purity vector manufacturing processes that support regulatory readiness and commercial viability. Higher dosing requirements, tighter impurity specifications, and the need for robust batch consistency are reshaping expectations for viral vector production.
Open in Who Shared Issue with article?

SK pharmteco CEO Interviewed at DCAT Week 2026 by Pharmaceutical Technology

|
By Bob Brousseau
| SK pharmteco
A Discussion of the CDMO Strategies Hear directly from Joerg Ahlgrimm, CEO of SK pharmteco, in this Pharmaceutical Technology video interview from DCAT Week 2026, where he discusses the company’s three-business-unit strategy, growth in cell and gene therapy, and the future of global CDMO operations.
Open in Who Shared Issue with article?

CGT Manufacturing Scale-Up: SK pharmteco Featured in GEN

|
By Bob Brousseau
| SK pharmteco
As cell and gene therapies move from early development toward clinical and commercial production, manufacturers face growing pressure to improve scalability, reliability, and speed. In a recent GEN article, SK pharmteco shares insights on the next wave of improvements shaping CGT manufacturing scale-up—from optimized lentiviral vector production to integrated solutions that help developers reduce risk as programs advance.
Open in Who Shared Issue with article?

SK pharmteco Collaborates with Axle Informatics and the National Institutes of Health to Advance Rare Disease Gene Therapy Programs

|
By Bob Brousseau
| SK pharmteco
Rancho Cordova, CA (May 6, 2026) — SK pharmteco today announced a strategic partnership with Axle Informatics and the National Institutes of Health (NIH) to advance the development of gene therapies for rare diseases. This partnership, focused on viral vector programs, underscores SK pharmteco’s commitment to the rare disease sector and its role as a key technical partner for leading research institutions.
Open in Who Shared Issue with article?

Addressing the ACN Supply by Implementing Recovery and Reuse Strategies

|
By Bob Brousseau
| SK pharmteco
Acetonitrile (ACN) demand is rising rapidly across peptide and oligonucleotide manufacturing, raising concerns about supply security, pricing, and sustainability. This work highlights how SK pharmteco is evaluating recovery and reuse strategies that can deliver high-purity ACN, reduce dependence on fresh solvent, reduce waste generation, and lower the contribution of raw materials to costs.
Open in Who Shared Issue with article?

SK pharmteco Journalists

Ahlgrimm, Joerg